PKI / Revvity Inc. - Документы SEC, Годовой отчет, Доверенное заявление

Реввити Инк.
US ˙ NYSE ˙ US7140461093
ЭТОТ СИМВОЛ БОЛЬШЕ НЕ АКТИВЕН

Основная статистика
LEI 549300IKL1SDPFI7N655
CIK 31791
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Revvity Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
August 5, 2025 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 29, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001

July 28, 2025 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization) (C

July 28, 2025 EX-99.1

Revvity Announces Financial Results for the Second Quarter of 2025

FOR IMMEDIATE RELEASE July 28, 2025 Revvity Announces Financial Results for the Second Quarter of 2025 •Revenue of $720 million; 4% reported growth; 3% organic growth •GAAP EPS of $0.

June 20, 2025 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K

11-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

May 30, 2025 SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.) 77 4th Avenue, Waltham, Massachusetts 02451 (Address of Principa

May 30, 2025 EX-1.01

Revvity, Inc. Conflict Minerals Report For the Year Ended December 31, 2024

Exhibit 1.01 Revvity, Inc. Conflict Minerals Report For the Year Ended December 31, 2024 Overview Revvity, Inc. (“Revvity” or the “Company”), is filing this Conflict Minerals Report (“Report”) pursuant to Rule 13p-1 and Form SD under the Securities Exchange Act of 1934 (the “Rule”), for the reporting period January 1, 2024 through December 31, 2024. The Rule requires companies that report under th

May 6, 2025 EX-3.2

Revvity, Inc.'s Amended and Restated By-laws, attached hereto as Exhibit 3.2.

1 Revvity, Inc. By-Laws Amended and Restated as of April 24, 2025 ARTICLE I. Stockholders. 1. Place of Meetings. All meetings of stockholders shall be held within Massachusetts unless the Articles of Organization permit the holding of stockholder meetings outside Massachusetts, in which event such meetings may be held either within or without Massachusetts. Meetings of stockholders shall be held a

May 6, 2025 EX-3.1

Revvity, Inc.'s Restated Articles of Organization, as amended, attached hereto as Exhibit 3.1.

FEDERAL IDENTIFICATION No. 04-2052042 The Commonwealth of Massachusetts William Francis Galvin Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 RESTATED ARTICLES OF ORGANIZATION (General UM) Chapter 156/3, Section 74) We, Terrance L. Carlson , *Vice President. and John L. Healy , *Assistant Clerk. of PerkinElmer, Inc. (Exact name of corporation) located at 45 Wil

May 6, 2025 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00

April 28, 2025 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization) (

April 28, 2025 EX-99.1

Revvity Announces Financial Results for the First Quarter of 2025

FOR IMMEDIATE RELEASE April 28, 2025 Revvity Announces Financial Results for the First Quarter of 2025 •Revenue of $665 million; 2% reported growth; 4% organic growth •GAAP EPS of $0.

April 25, 2025 EX-3.2

Articles of Correction to Restated Articles of Organization, as amended, effective as of April 23, 2025.

Exhibit 3.2 MA SOC  Filing Number: 202546472640  Date: 4/23/2025 6:25:12 PM Docusign Envelope ID: DF440732-4AE5-4527-A5CE-8D26F4B40769 William Francis Galvin Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 FORM MUST BE TYPED Articles of Correction FORM MUST BE TYPED (General Laws Chapter 156D, Section 1.24, 950 CMR 113.12) (1) Exact name of corporation: Revvity,

April 25, 2025 EX-3.3

Amended and Restated By-laws, redlined for amendments effective as of April 24, 2025.

Exhibit 3.3 REVVITY, INC. BY-LAWS Amended and Restated as of April 246, 20253 ARTICLE I. Stockholders. 1. Place of Meetings. All meetings of stockholders shall be held within Massachusetts unless the Articles of Organization permit the holding of stockholder meetings outside Massachusetts, in which event such meetings may be held either within or without Massachusetts. Meetings of stockholders sha

April 25, 2025 8-K

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commission File

April 25, 2025 EX-3.1

Articles of Amendment to Restated Articles of Organization, as amended, effective as of April 23, 2025.

Exhibit 3.1 William Francis Galvin Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 FORM MUST BE TYPED Articles of Amendment FORM MUST BE TYPED (General Laws Chapter 156D, Section 10.06; 950 CMR 113.34) (1) Exact name of corporation: Revvity, Inc.                                   (2) Registered office address: 155 Federal Street, Suite 700, Boston, Massachusetts

March 12, 2025 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by th e Re gistrant ☒       Filed by a party other than the R egistran t ☐ Check the appropriate box: ☐ Preliminary Proxy Statemen

March 12, 2025 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒       Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidenti

February 28, 2025 S-3ASR

As filed with the Securities and Exchange Commission on February 28, 2025

As filed with the Securities and Exchange Commission on February 28, 2025 Registration No.

February 28, 2025 EX-FILING FEES

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For

February 28, 2025 EX-25.1

The Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of U.S. Bank Trust Company, National Association under the Senior Indenture

Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. E

February 26, 2025 PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒       Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐

February 25, 2025 EX-21

Subsidiaries of Revvity, Inc., attached hereto as Exhibit 21.

EXHIBIT 21 Subsidiaries of the Registrant As of February 25, 2025, following please find a list of Revvity, Inc.

February 25, 2025 EX-19

Securities Trading Policy dated as of February 11, 2025, attached hereto as Exhibit 19.

EXHIBIT 19 M E M O R A N D U M TO: All Revvity Employees Board of Directors FROM: Joel S.

February 25, 2025 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 29, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-5075 Revvity, Inc.

January 31, 2025 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2025 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization)

January 31, 2025 EX-99.1

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024

FOR IMMEDIATE RELEASE January 31, 2025 Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024 •Fourth quarter revenue of $729 million; 5% reported growth; 6% organic growth •Fourth quarter GAAP EPS of $0.

January 13, 2025 EX-99.2

J.P. Morgan Healthcare Conference January 13, 2025 Safe Harbor 2 This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to e

jpm2025final J.P. Morgan Healthcare Conference January 13, 2025 Safe Harbor 2 This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to

January 13, 2025 EX-99.1

Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance

Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance WALTHAM, Mass.

January 13, 2025 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization)

January 7, 2025 EX-99.1

CREDIT AGREEMENT Dated as of January 7, 2025 REVVITY, INC., REVVITY HEALTH SCIENCES, INC., CERTAIN OTHER SUBSIDIARIES OF REVVITY, INC., as the Borrowers, BANK OF AMERICA, N.A., as the Administrative Agent, the Swing Line Lender and an L/C Issuer, JPM

Exhibit 99.1 EXECUTION VERSION CUSIP Numbers: Deal: 76156EAA9 Revolver: 76156EAB7 CREDIT AGREEMENT Dated as of January 7, 2025 among REVVITY, INC., REVVITY HEALTH SCIENCES, INC., and CERTAIN OTHER SUBSIDIARIES OF REVVITY, INC., as the Borrowers, BANK OF AMERICA, N.A., as the Administrative Agent, the Swing Line Lender and an L/C Issuer, JPMORGAN CHASE BANK, N.A., GOLDMAN SACHS BANK USA, PNC BANK,

January 7, 2025 8-K

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commission File

December 4, 2024 EX-FILING FEES

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Other Deferred Compensation  Obligations(1) 

December 4, 2024 S-8

As filed with the Securities and Exchange Commission on December 4, 2024

As filed with the Securities and Exchange Commission on December 4, 2024 Registration No.

December 4, 2024 EX-99.4

Third Amendment to 2008 Deferred Compensation Plan

Exhibit 99.4 Revvity, Inc. 2008 Deferred Compensation Plan Third Amendment WHEREAS, Revvity, Inc., a Massachusetts corporation (the “Company”) maintains the Revvity, Inc. 2008 Deferred Compensation Plan, f/k/a the PerkinElmer, Inc. 2008 Deferred Compensation Plan (the “Plan”), as amended by the First Amendment dated December 17, 2010 (the “First Amendment”) and the Second Amendment dated March 23,

November 14, 2024 SC 13G/A

RVTY / Revvity, Inc. / Select Equity Group, L.P. - SCHEDULE 13G/A, (AMENDMENT NO. 2) Passive Investment

SC 13G/A 1 s013024a.htm SCHEDULE 13G/A, (AMENDMENT NO. 2) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Revvity, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 714046109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to design

November 14, 2024 EX-99.1

EXHIBIT 99.1

EX-99.1 2 s013124a.htm EXHIBIT 99.1 EXHIBIT 99.1 The identity and the Item 3 classification of the relevant subsidiary are: Select Equity Group, L.P., which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

November 12, 2024 SC 13G/A

RVTY / Revvity, Inc. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11 )* Revvity, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 714046109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

November 6, 2024 EX-3.1

Restated Articles of Organization, as amended, of the Registrant

FEDERAL IDENTIFICATION No. 04-2052042 The Commonwealth of Massachusetts William Francis Galvin Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 RESTATED ARTICLES OF ORGANIZATION (General UM) Chapter 156/3, Section 74) We, Terrance L. Carlson , *Vice President. and John L. Healy , *Assistant Clerk. of PerkinElmer, Inc. (Exact name of corporation) located at 45 Wil

November 6, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 29, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe

November 4, 2024 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization)

November 4, 2024 EX-99.1

Revvity Announces Financial Results for the Third Quarter of 2024

FOR IMMEDIATE RELEASE November 4, 2024 Revvity Announces Financial Results for the Third Quarter of 2024 •Revenue of $684 million; 2% reported growth; 2% organic growth •GAAP EPS of $0.

August 6, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001

July 29, 2024 EX-99.1

Revvity Announces Financial Results for the Second Quarter of 2024

FOR IMMEDIATE RELEASE July 29, 2024 Revvity Announces Financial Results for the Second Quarter of 2024 •Revenue of $692 million; (2)% reported growth; (1)% organic growth •GAAP EPS of $0.

July 29, 2024 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization) (C

June 27, 2024 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from       to       Commission File Number 001-050

May 31, 2024 SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.) 940 Winter Street, Waltham, Massachusetts 02451 (Address of Prin

May 31, 2024 EX-1.01

Revvity, Inc. Conflict Minerals Report For the Year Ended December 31, 2023

Exhibit 1.01 Revvity, Inc. Conflict Minerals Report For the Year Ended December 31, 2023 Overview Revvity, Inc. (“Revvity” or the “Company”), is filing this Conflict Minerals Report (“Report”) pursuant to Rule 13p-1 and Form SD under the Securities Exchange Act of 1934 (the “Rule”), for the reporting period January 1, 2023 through December 31, 2023. The Rule requires companies that report under th

May 7, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00

April 29, 2024 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization) (

April 29, 2024 EX-99.1

Revvity Announces Financial Results for the First Quarter of 2024

FOR IMMEDIATE RELEASE April 29, 2024 Revvity Announces Financial Results for the First Quarter of 2024 •Revenue of $650 million; (4)% reported growth; (3)% organic growth •First quarter GAAP EPS of $0.

April 24, 2024 8-K

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commission File

March 13, 2024 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒       Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for

March 13, 2024 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒       Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for

February 27, 2024 EX-21

Subsidiaries of Revvity, Inc., attached hereto as Exhibit 21.

EXHIBIT 21 Subsidiaries of the Registrant As of February 27, 2024, following please find a list of Revvity, Inc.

February 27, 2024 EX-10.31

Form of Restricted Stock Unit Agreement (Time-based vesting) with single-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan,

Time-Vested RSU (Single Trigger) Exhibit 10.31 REVVITY, INC. Restricted Stock Unit Agreement 2019 Stock Incentive Plan This Restricted Stock Unit Agreement is made as of the Grant Date set forth below between Revvity, Inc., a Massachusetts corporation (the “Company”), and the Participant named below. NOTICE OF GRANT Name of Participant (the “Participant”): Grant Date: Number of Restricted Stock Un

February 27, 2024 EX-10.28

Form of Stock Option Agreement with double-trigger vesting acceleration following a change of control for grants to executive officers under the 2019 Incentive Plan, attached hereto as Exhibit 10.2

2019OFOPDT – Officer Stock Option Double-Trigger Exhibit 10.28 REVVITY, INC. Nonstatutory Stock Option Agreement 2019 Stock Incentive Plan This Nonstatutory Stock Option Agreement is made as of the Grant Date set forth below between Revvity, Inc., a Massachusetts corporation (the “Company”), and the optionee named below. NOTICE OF GRANT Name of optionee (“you”): Grant Date: Number of shares of the

February 27, 2024 EX-10.12

Revvity, Inc. Amended and Restated Global Incentive Compensation Plan (Executive Officers) effective

EXHIBIT 10.12 Revvity, Inc. Global Incentive Compensation Plan (Executive Officers) effective as of October 2, 2023 1. PURPOSE 1.1 The Global Incentive Compensation Plan(“Plan”) provides senior and other key leaders with an opportunity to earn annual cash bonus awards based on the achievement of financial and non-financial objectives. This document governs the policy and administration of the Plan

February 27, 2024 EX-10.27

Form of Stock Option Agreement with single-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, attached hereto as Exhibit 10.2

2019OFFOPT – Officer Stock Option Single Trigger EXHIBIT 10.27 REVVITY, INC. Nonstatutory Stock Option Agreement 2019 Stock Incentive Plan This Nonstatutory Stock Option Agreement is made as of the Grant Date set forth below between Revvity, Inc., a Massachusetts corporation (the “Company”), and the optionee named below. NOTICE OF GRANT Name of optionee (“you”): Grant Date: Number of shares of the

February 27, 2024 EX-10.29

Form of Restricted Stock Unit Agreement (Performance-based vesting) with single-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan,

Performance RSU (Single Trigger) Exhibit 10.29 REVVITY, INC. Restricted Stock Unit Agreement 2019 Incentive Plan This Restricted Stock Unit Agreement is made as of the Grant Date set forth below between Revvity, Inc., a Massachusetts corporation (the “Company”), and the Participant named below. NOTICE OF GRANT Name of Participant (the “Participant”): [PARTICIPANT NAME] Grant Date: [GRANT DATE] Num

February 27, 2024 EX-10.30

Form of Restricted Stock Unit Agreement (Performance-based vesting) with double-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, filed with the Commission on February 27, 2024 as Exhibit 10.30 to our annual report on Form 10-K (File No. 001-05075) and herein incorporated by reference.

Officer Performance RSU (Double Trigger) Exhibit 10.30 REVVITY, INC. Restricted Stock Unit Agreement 2019 Incentive Plan This Restricted Stock Unit Agreement is made as of the Grant Date set forth below between Revvity, Inc., a Massachusetts corporation (the “Company”), and the Participant named below. NOTICE OF GRANT Name of Participant (the “Participant”): [PARTICIPANT NAME] Grant Date: [GRANT D

February 27, 2024 EX-10.32

Form of Restricted Stock Unit Agreement (Time-based vesting) with double-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, filed with the Commission on February 27, 2024 as Exhibit 10.32 to our annual report on Form 10-K (File No. 001-05075) and herein incorporated by reference.

Time-Vested RSU (Double Trigger) Exhibit 10.32 REVVITY, INC. Restricted Stock Unit Agreement 2019 Stock Incentive Plan This Restricted Stock Unit Agreement is made as of the Grant Date set forth below between Revvity, Inc., a Massachusetts corporation (the “Company”), and the Participant named below. NOTICE OF GRANT Name of Participant (the “Participant”): Grant Date: Number of Restricted Stock Un

February 27, 2024 EX-97

Revvity, Inc. Dodd-Frank Compensation Recovery Policy effective October 2, 2023, attached hereto as Exhibit 97.

EXHIBIT 97 REVVITY, INC. Dodd-Frank Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Revvity, Inc. (the “Company”) in accordance with Section 303A.14 of the New York Stock Exchange (“NYSE”) Listed Company Manual (“Section 303A.14”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (as promulgated purs

February 27, 2024 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-5075 Revvity, Inc.

February 14, 2024 SC 13G/A

RVTY / Revvity, Inc. / Select Equity Group, L.P. - SCHEDULE 13G (AMENDMENT NO. 1) Passive Investment

SC 13G/A 1 s013024a.htm SCHEDULE 13G (AMENDMENT NO. 1) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Revvity, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 714046109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate

February 14, 2024 EX-99.1

EXHIBIT 99.1

EX-99.1 2 s013124a.htm EXHIBIT 99.1 EXHIBIT 99.1 The identity and the Item 3 classification of the relevant subsidiary are: Select Equity Group, L.P., which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

February 13, 2024 SC 13G/A

RVTY / Revvity, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01821-revvityinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 15)* Name of issuer: Revvity Inc Title of Class of Securities: Common Stock CUSIP Number: 714046109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule p

February 9, 2024 SC 13G/A

RVTY / Revvity, Inc. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10 )* Revvity, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 714046109 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi

February 1, 2024 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 Revvity, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization)

February 1, 2024 EX-99.1

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023

Exhibit 99.1 Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023 Fourth quarter revenue of $696 million; (6)% reported growth; (7)% organic growth; (3)% non-COVID organic growth Fourth quarter GAAP EPS of $0.64; Adjusted EPS from continuing operations of $1.25 Initiates full year 2024 guidance WALTHAM, Mass.-(BUSINESS WIRE)-February 1, 2024-Revvity, Inc. (NYSE: RVTY),

January 26, 2024 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization)

January 9, 2024 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Revvity, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization)

January 9, 2024 EX-99.1

Revvity to Hold Earnings Call on Thursday, February 1, 2024; Provides Update on Financial Performance

Exhibit 99.1 Revvity to Hold Earnings Call on Thursday, February 1, 2024; Provides Update on Financial Performance WALTHAM, Mass.-(BUSINESS WIRE)-January 9, 2024-Revvity, Inc. (NYSE: RVTY) today announced that it will release its fourth quarter and full year 2023 financial results prior to market open on Thursday, February 1, 2024. The Company will host a conference call the same day at 8:00 a.m.

January 9, 2024 EX-99.2

J.P. Morgan42nd Healthcare Conference Prahlad Singh Chief Executive Officer January 9, 2024 Safe Harbor This presentation contains "forward-looking" statements which are statements relating to future events. These statements include those relating to

Exhibit 99.2 J.P. Morgan42nd Healthcare Conference Prahlad Singh Chief Executive Officer January 9, 2024 Safe Harbor This presentation contains "forward-looking" statements which are statements relating to future events. These statements include those relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating

November 7, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 1, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0

October 30, 2023 EX-99.1

Revvity Announces Financial Results for the Third Quarter of 2023

Exhibit 99.1 Revvity Announces Financial Results for the Third Quarter of 2023 Revenue of $671 million; (6)% reported growth; (7)% organic growth; 1% non-COVID organic growth GAAP EPS of $0.08; Adjusted EPS from continuing operations of $1.18 Updates full year 2023 guidance WALTHAM, Mass.-(BUSINESS WIRE)-October 30, 2023-Revvity, Inc. (NYSE: RVTY), today reported financial results for the third qu

October 30, 2023 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization)

August 9, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 2, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-

August 9, 2023 EX-10.1

First Amendment to Credit Agreement, dated as of April 24, 2023, among PerkinElmer, Inc., PerkinElmer Health Sciences, Inc., PerkinElmer Life Sciences International Holdings, PerkinElmer Global Holdings S.à r.l. and PerkinElmer Health Sciences B.V. as Borrowers, Bank of America, N.A. as Administrative Agent, Swing Line Lender and an L/C Issuer, the Lenders party thereto and the other L/C Issuers party thereto, attached hereto as Exhibit 10.1.

EXECUTION VERSION FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is entered into as of April 24, 2023 (the “First Amendment Effective Date”) among PERKINELMER, INC.

August 1, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 Revvity, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization) (

August 1, 2023 EX-99.1

Revvity Announces Financial Results for the Second Quarter of 2023

Exhibit 99.1 Revvity Announces Financial Results for the Second Quarter of 2023 Revenue of $709 million; (21)% reported growth; (20)% organic growth; 6% non-COVID organic growth GAAP EPS of $0.28; Adjusted EPS from continuing operations of $1.21 Updates full year 2023 guidance WALTHAM, Mass.-(BUSINESS WIRE)-August 1, 2023-Revvity, Inc. (NYSE: RVTY), today reported financial results for the second

July 21, 2023 11-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Amendment No. 1)

11-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

June 28, 2023 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K

11-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

May 31, 2023 SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Inco

Form SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.) 940 Winter Street, Waltham, Massachusetts 02451 (Address

May 31, 2023 EX-1.01

Revvity, Inc. Conflict Minerals Report For the Year Ended December 31, 2022

EX-1.01 Exhibit 1.01 Revvity, Inc. Conflict Minerals Report For the Year Ended December 31, 2022 Overview Revvity, Inc., formerly known as PerkinElmer, Inc. (“Revvity” or the “Company”), is filing this Conflict Minerals Report (“Report”) pursuant to Rule 13p-1 and Form SD under the Securities Exchange Act of 1934 (the “Rule”), for the reporting period January 1, 2022 through December 31, 2022. The

May 12, 2023 EX-3.2

Amended and Restated By-laws, attached hereto as Exhibit 3.2.

REVVITY, INC. BY-LAWS Amended and Restated as of April 26, 2023 ARTICLE I. Stockholders. 1. Place of Meetings. All meetings of stockholders shall be held within Massachusetts unless the Articles of Organization permit the holding of stockholder meetings outside Massachusetts, in which event such meetings may be held either within or without Massachusetts. Meetings of stockholders shall be held at

May 12, 2023 EX-3.1

Restated Articles of Organization, as amended, attached hereto as Exhibit 3.1.

FEDERAL IDENTIFICATION No. 04-2052042 The Commonwealth of Massachusetts William Francis Galvin Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 RESTATED ARTICLES OF ORGANIZATION (General Laws, Chapter 156B, Section 74) We, Terrance L. Carlson , *Vice President. and John L. Healy , *Assistant Clerk. of PerkinElmer, Inc. (Exact name of corporation) located at 45 Wi

May 12, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 2, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001

May 11, 2023 EX-99.1

Revvity Announces Financial Results for the First Quarter of 2023

Exhibit 99.1 Revvity Announces Financial Results for the First Quarter of 2023 Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin trading under new ticker “RVTY” on May 16th WALTHAM, Mass.-(B

May 11, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Revvity, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization) (Co

April 28, 2023 EX-3.2

Amended and Restated By-laws, redlined for amendments effective April 26, 2023.

EX-3.2 Exhibit 3.2 PERKINELMERREVVITY, INC. BY- LAWS Amended and Restated as of December 7April 26, 20182023 ARTICLE I. Stockholders. 1. Place of Meetings. All meetings of stockholders shall be held within Massachusetts unless the Articles of Organization permit the holding of stockholder meetings outside Massachusetts, in which event such meetings may be held either within or without Massachusett

April 28, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 Revvity, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 Revvity, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commission File

April 28, 2023 EX-3.1

Articles of Amendment to Amended and Restated Articles of Organization, as amended.

EX-3.1 Exhibit 3.1 The Commonmealth of Massachusetts William Francis Galvin Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 Articles of Amendment (General Laws Chapter 156D, Section 10.06; 950 CMR 113.34) (1) Exact name of corporation: PerkinElmer, Inc. (2) Registered office address: 155 Federal Street, Boston, Massachusetts 02110 (number, street, city or town,

March 16, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2023 PerkinElmer, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2023 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commission F

March 16, 2023 EX-2.1

Amended and Restated Master Purchase and Sale Agreement, dated as of March 11, 2023, by and between PerkinElmer, Inc., PerkinElmer U.S. LLC and PerkinElmer Topco, L.P.

EX-2.1 Exhibit 2.1 Execution Version AMENDED AND RESTATED MASTER PURCHASE AND SALE AGREEMENT BY AND AMONG PERKINELMER, INC., PERKINELMER U.S. LLC, and PERKINELMER TOPCO, L.P. March 11, 2023 TABLE OF CONTENTS Page ARTICLE I EQUITY INTEREST AND ASSET PURCHASE 3 1.1   Sale and Transfer of Equity Interests and Assets; Assumption of Liabilities 3 1.2   Purchase Price, Locked Box and Related Matters 18

March 8, 2023 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid

March 8, 2023 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A ++++ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidentia

March 1, 2023 EX-21

Subsidiaries of PerkinElmer, Inc., attached hereto as Exhibit 21.

EXHIBIT 21 Subsidiaries of the Registrant As of March 1, 2023, the following is a list of the parent (Registrant) and its active subsidiaries, together with their subsidiaries.

March 1, 2023 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 1, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-5075 PerkinElmer, Inc.

February 14, 2023 EX-99.2

AGREEMENT OF REPORTING PERSONS

EX-99.2 3 s60891316c.htm AGREEMENT OF REPORTING PERSONS EXHIBIT 99.2 AGREEMENT OF REPORTING PERSONS The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint f

February 14, 2023 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organiza

February 14, 2023 SC 13G/A

PKI / PerkinElmer, Inc. / Select Equity Group, L.P. - SCHEDULE 13G/A, AMENDMENT #5 Passive Investment

SC 13G/A 1 s60891316a.htm SCHEDULE 13G/A, AMENDMENT #5 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* PerkinElmer, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 714046109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to desi

February 14, 2023 EX-99.1

PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2022

Exhibit 99.1 PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2022 Fourth quarter revenue from continuing operations of $741 million; (28)% reported growth; (23)% organic growth; 8% non-COVID organic growth Combined* total fourth quarter revenue of $1,089 million; 8% combined non-COVID organic growth Fourth quarter GAAP EPS from continuing operations of $0.85; combin

February 14, 2023 EX-99.1

EXHIBIT 99.1

EX-99.1 2 s60891316b.htm THE IDENTITY AND THE ITEM 3 CLASSIFICATION OF THE RELEVANT SUBSIDIARY EXHIBIT 99.1 The identity and the Item 3 classification of the relevant subsidiary are: Select Equity Group, L.P., which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

February 13, 2023 SC 13G/A

PKI / PerkinElmer, Inc. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9 )* PerkinElmer, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 714046109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d

February 9, 2023 SC 13G/A

PKI / PerkinElmer, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01659-perkinelmerinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 14)* Name of issuer: PerkinElmer Inc. Title of Class of Securities: Common Stock CUSIP Number: 714046109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate t

January 9, 2023 EX-99.1

PerkinElmer To Hold Earnings Call on Tuesday, February 14, 2023; Updates Fourth Quarter Outlook

Exhibit 99.1 PerkinElmer To Hold Earnings Call on Tuesday, February 14, 2023; Updates Fourth Quarter Outlook WALTHAM, Mass.-(BUSINESS WIRE)-January 9, 2023-PerkinElmer Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it will release its fourth quarter and full year 2022 financial results prior to market open on Tuesday, February 14, 2023. The C

January 9, 2023 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizati

November 14, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 2, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0

November 8, 2022 EX-99.1

PerkinElmer Announces Financial Results for the Third Quarter of 2022

Exhibit 99.1 PerkinElmer Announces Financial Results for the Third Quarter of 2022 Third quarter revenue of $712 million; (17)% reported growth Pro forma* total revenue of $1,033 million; 9% pro forma non-COVID organic growth Third quarter GAAP EPS from continuing operations of $0.55; pro forma adjusted EPS of $1.51 Initiates fourth quarter and updates full year pro forma guidance WALTHAM, Mass.-(

November 8, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizat

October 17, 2022 EX-99.1

PerkinElmer to Hold Earnings Call on Tuesday, November 8, 2022; Updates Third Quarter Outlook

Exhibit 99.1 PerkinElmer to Hold Earnings Call on Tuesday, November 8, 2022; Updates Third Quarter Outlook WALTHAM, Mass.-(BUSINESS WIRE)-October 17, 2022-PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced it will release its full third quarter 2022 financial results on November 8, 2022. Management will host a webcast the same day at 8:00

October 17, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2022 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizat

August 17, 2022 EX-99.1

EMPLOYMENT AGREEMENT

Exhibit 99.1 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) effective as of September 6, 2022 between PerkinElmer, Inc., a Massachusetts corporation (hereinafter called the ?Company?), and Maxwell Krakowiak (hereinafter referred to as the ?Employee?). WITNESSETH: WHISEAS, the Company wishes to employ the Employee in a management position; and WHISEAS, the Employee hereby agrees t

August 17, 2022 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizati

August 9, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 3, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-

August 5, 2022 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commission F

August 5, 2022 EX-2.1

Master Purchase and Sale Agreement, dated as of August 1, 2022, by and between PerkinElmer, Inc. and Polaris Purchaser, L.P., filed with the Commission on August 5, 2022 as Exhibit 2.1 to our current report on Form 8-K (File No. 001-05075) and herein incorporated by reference.

Exhibit 2.1 EXECUTION VERSION MASTER PURCHASE AND SALE AGREEMENT BY AND BETWEEN PERKINELMER, INC. and POLARIS PURCHASER, L.P. AUGUST 1, 2022 TABLE OF CONTENTS Page ARTICLE I EQUITY INTEREST AND ASSET PURCHASE 3 1.1 Sale and Transfer of Equity Interests and Assets; Assumption of Liabilities 3 1.2 Purchase Price and Related Matters 15 1.3 The Closing 16 1.4 Post-Closing Adjustment 19 1.5 Deferred Pa

August 1, 2022 EX-99.1

PerkinElmer Announces Financial Results for the Second Quarter of 2022

Exhibit 99.1 PerkinElmer Announces Financial Results for the Second Quarter of 2022 Signs agreement with the intention to divest Applied, Food, and Enterprise Services businesses Second quarter revenue of $1.23 billion; 0% reported growth, 8% non-COVID organic growth Second quarter GAAP EPS from continuing operations of $1.42; adjusted EPS of $2.32 Initiates third quarter and raises full year guid

August 1, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizatio

July 22, 2022 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2022 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization

July 8, 2022 CORRESP

PerkinElmer, Inc.

PerkinElmer, Inc. 940 Winter Street Waltham, MA 02451 USA Phone 781.663.6900 Fax 781.663.6052 www.perkinelmer.com July 8, 2022 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Ms. Lynn Dicker cc: Ms. Tara Harkins RE: Response to Comment Letter dated June 30, 2022 PerkinElmer, Inc. File No. 001-05075 Related to the filing on Form

June 9, 2022 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-05075 A. Full t

May 31, 2022 SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of

SD 1 d355664dsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.) 940 Winter Street, Waltham, Massachus

May 31, 2022 EX-1.01

PerkinElmer, Inc. Conflict Minerals Report For the Year Ended December 31, 2021

Exhibit 1.01 PerkinElmer, Inc. Conflict Minerals Report For the Year Ended December 31, 2021 Overview PerkinElmer, Inc. (?PerkinElmer? or the ?Company?) is filing this Conflict Minerals Report (?Report?) pursuant to Rule 13p-1 and Form SD under the Securities Exchange Act of 1934 (the ?Rule?), for the reporting period January 1, 2021 through December 31, 2021. The Rule requires companies that repo

May 10, 2022 EX-10.1

22 as Exhibit 10.1 to our quarterly report on Form 10-Q (File No. 001-05075) and herein incorporated by reference

EXHIBIT 10.1 PerkinElmer, Inc. 2008 Deferred Compensation Plan Second Amendment WHEREAS, PerkinElmer, Inc., a Massachusetts corporation (the ?Company?) maintains the PerkinElmer, Inc. 2008 Deferred Compensation Plan (the ?Plan?), as amended by the First Amendment dated December 17, 2010 (the ?First Amendment?); WHEREAS, the Plan was closed to future voluntary contributions effective January 1, 201

May 10, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 3, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001

May 3, 2022 EX-99.1

PerkinElmer Announces Financial Results for the First Quarter of 2022

Exhibit 99.1 PerkinElmer Announces Financial Results for the First Quarter of 2022 First quarter revenue of $1.26 billion First quarter GAAP EPS from continuing operations of $1.40; Adjusted EPS of $2.41 Initiates Second Quarter and Raises Full Year Guidance WALTHAM, Mass.-(BUSINESS WIRE)-May 3, 2022-PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, toda

May 3, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization)

April 29, 2022 8-K

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commission F

April 1, 2022 8-K

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizatio

March 25, 2022 EX-4.4

Form of Subordinated Note

Exhibit 4.4 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE

March 25, 2022 EX-4.2

Form of Subordinated Indenture

Exhibit 4.2 PERKINELMER, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inap

March 25, 2022 S-3ASR

As filed with the Securities and Exchange Commission on March 25, 2022

Table of Contents As filed with the Securities and Exchange Commission on March 25, 2022 Registration No.

March 25, 2022 EX-FILING FEES

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PerkinElmer, Inc.

March 25, 2022 S-8

As filed with the Securities and Exchange Commission on March 25, 2022

As filed with the Securities and Exchange Commission on March 25, 2022 Registration No.

March 25, 2022 EX-25.1

The Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of U.S. Bank Trust Company, National Association under the Senior Indenture

Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. E

March 25, 2022 EX-99.1

2008 Deferred Compensation Plan, as amended

Exhibit 99.1 PERKINELMER, INC. 2008 DEFERRED COMPENSATION PLAN as of January 1, 2008 TABLE OF CONTENTS ARTICLE 1 Purpose and Construction 1 1.1 Purpose. 1 1.2 Status of Plan. 1 1.3 Effective Date. 1 ARTICLE 2 Definitions 2 2.1 ?Account? 2 2.2 ?Administrator? 2 2.3 ?Base Salary? 2 2.4 ?Beneficiary? 2 2.5 ?Board? 2 2.6 ?Change in Control? 2 2.7 ?Code? 3 2.8 ?Committee? 3 2.9 ?Company? 3 2.10 ?Compan

March 25, 2022 EX-FILING FEES

Filing Fee Table

EX-FILING FEES 7 d293052dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate

March 9, 2022 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 d94646ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy

March 9, 2022 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid

March 3, 2022 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 2, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-5075 PerkinElmer, Inc.

March 3, 2022 EX-4.2

Description of PerkinElmer, Inc.’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, attached hereto as Exhibit 4.2

Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of January 2, 2022, PerkinElmer, Inc. (?we? or ?us?) had two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): (1) our common stock, $1.00 par value per share; and (2) our 1.875% Notes due 2026 (t

March 3, 2022 EX-21

Subsidiaries of PerkinElmer, Inc., attached hereto as Exhibit 21.

EXHIBIT 21 Subsidiaries of the Registrant As of March 3, 2022, the following is a list of the parent (Registrant) and its active subsidiaries, together with their subsidiaries.

March 3, 2022 EX-10.3(8)

(5) Employment Agreement between Miriame Victor and Revvity, Inc. dated as of January 1, 2022, filed with the Commission on March 3, 2022 as Exhibit 10.3(8) to our annual report on Form 10-K (File No. 001-05075) and herein incorporated by reference.

Exhibit 10.3(8) EMPLOYMENT AGREEMENT Effective January 1st, 2022, this Employment Agreement (the ?Agreement?) between PerkinElmer, Inc., a Massachusetts corporation (hereinafter called the ?Company?), and Miriame Victor (hereinafter referred to as the ?Employee?). WITNESSETH: WHEREAS, the Company wishes to employ the Employee in a management position; and WHEREAS, the Employee hereby agrees to the

February 14, 2022 EX-99.1

EXHIBIT 99.1

EXHIBIT 99.1 The identity and the Item 3 classification of the relevant subsidiary are: Select Equity Group, L.P., which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

February 14, 2022 SC 13G/A

PKI / PerkinElmer, Inc. / Select Equity Group, L.P. - SCHEDULE 13G/A, #4 Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* PerkinElmer, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 714046109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed

February 11, 2022 SC 13G/A

PKI / PerkinElmer, Inc. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8 )* PerkinElmer, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 714046109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

February 10, 2022 SC 13G/A

PKI / PerkinElmer, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: PerkinElmer Inc. Title of Class of Securities: Common Stock CUSIP Number: 714046109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??R

February 1, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2022 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizat

February 1, 2022 EX-99.1

PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2021

Exhibit 99.1 PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2021 4Q Revenue of $1.36 billion; 1% reported growth; -9% organic growth 4Q GAAP EPS from continuing operations of $1.41; Adjusted EPS of $2.56 Initiates First Quarter and Full Year 2022 Guidance WALTHAM, Mass.-(BUSINESS WIRE)-February 1, 2022-PerkinElmer, Inc. (NYSE: PKI), a global leader committed to inn

January 11, 2022 EX-99.1

PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 1, 2022

Exhibit 99.1 PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 1, 2022 Fourth quarter 2021 revenue and earnings per share to exceed prior guidance Non-COVID organic growth in fourth quarter 2021 of approximately 10% Fourth quarter 2021 COVID product and services related revenue of approximately $320 million WALTHAM, Mass.-(BUSINESS WIRE)-January 11, 2022-Perkin

January 11, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizat

November 9, 2021 10-Q

Number of Shares Weighted- Average Grant- Date Fair Value (In thousands) Nonvested at January 3, 2021 296 $ 85.67 Granted 102 129.27 Vested (102) 83.16 Forfeited (5) 86.90 Nonvested at October 3, 2021 291 $ 101.83

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 3, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0

November 4, 2021 EX-99.3

Year ended December 31,

Exhibit 99.3 BioLegend, Inc. and subsidiaries Index to financial statements Audited Consolidated Financial Statements Report of Independent Auditors 2 Consolidated Balance Sheet as of December 31, 2020 3 Consolidated Statement of Income for the Year Ended December 31, 2020 4 Consolidated Statement of Comprehensive Income for the Year Ended December 31, 2020 5 Consolidated Statement of Stockholders

November 4, 2021 EX-99.5

PERKINELMER, INC. AND SUBSIDIARIES PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS FOR PERKINELMER, INC. AND BIOLEGEND, INC. (amounts in thousands, unless otherwise noted)

Exhibit 99.5 PERKINELMER, INC. AND SUBSIDIARIES PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS FOR PERKINELMER, INC. AND BIOLEGEND, INC. (Unaudited) (amounts in thousands, unless otherwise noted) PerkinElmer, Inc. and its subsidiaries are referred to herein collectively as the ?Company?. On September 17, 2021, the Company, through its direct, wholly owned subsidiaries, Burton Acquisition I, Inc

November 4, 2021 EX-99.4

1

Exhibit 99.4 BioLegend, Inc. and subsidiaries Index to financial statements Unaudited Interim Condensed Consolidated Financial Statements Unaudited Condensed Consolidated Balance Sheet as of June 30, 2021 2 Unaudited Condensed Consolidated Statements of Income for the Six Months Ended June 30, 2020 and 2021 3 Unaudited Condensed Consolidated Statements of Comprehensive Income for the Six Months En

November 4, 2021 8-K/A

Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Inco

November 2, 2021 EX-99.1

PerkinElmer Announces Financial Results for the Third Quarter of 2021

Exhibit 99.1 PerkinElmer Announces Financial Results for the Third Quarter of 2021 Revenue of $1.17 billion; 21% reported growth; 12% organic growth GAAP EPS from continuing operations of $1.11; Adjusted EPS of $2.31 Initiates Fourth Quarter Guidance and Raises Full Year Revenue and Earnings Guidance WALTHAM, Mass.-(BUSINESS WIRE)-November 2, 2021-PerkinElmer, Inc. (NYSE: PKI), a global leader com

November 2, 2021 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizat

October 1, 2021 8-K

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commission

October 1, 2021 424B7

CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price Per Share (2) Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee (3) Common stock, $1

Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-230425 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price Per Share (2) Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee (3) Common stock, $1 par value per share 14,066,771 $172.53 $2,426,940,000.63 $224,977.34 (

September 21, 2021 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commissi

September 10, 2021 EX-4.2

Seventh Supplemental Indenture, dated as of September 10, 2021, by and between the Company and U.S. Bank National Association, as trustee (including the form of note contained therein) filed with the Commission on September 10, 2021 as Exhibit 4.2 to our current report on Form 8-K (file No. 001-05075)) and herein incorporated by reference.

Exhibit 4.2 PERKINELMER, INC. $500,000,000 0.550% Senior Notes due 2023 $800,000,000 0.850% Senior Notes due 2024 $500,000,000 1.900% Senior Notes due 2028 $500,000,000 2.250% Senior Notes due 2031 SEVENTH SUPPLEMENTAL INDENTURE Dated as of September 10, 2021 to Indenture Dated as of October 25, 2011 U.S. Bank National Association, as Trustee This SEVENTH SUPPLEMENTAL INDENTURE (this ?Supplemental

September 10, 2021 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commissi

September 10, 2021 EX-1.1

Underwriting Agreement, dated September 8, 2021, by and among the Company and Goldman Sachs & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named in the Underwriting Agreement.

Exhibit 1.1 PerkinElmer, Inc. $2,300,000,000 0.550% Senior Notes due 2023 0.850% Senior Notes due 2024 1.900% Senior Notes due 2028 2.250% Senior Notes due 2031 UNDERWRITING AGREEMENT September 8, 2021 TABLE OF CONTENTS PAGE Section 1. Representations and Warranties of the Company 5 Section 2. Purchase, Sale and Delivery of the Notes 17 Section 3. Covenants of the Company 18 Section 4. Payment of

September 9, 2021 FWP

Final Term Sheet

Final Term Sheet Free Writing Prospectus Filed pursuant to Rule 433 To Prospectus dated March 21, 2019 Preliminary Prospectus Supplement dated September 8, 2021 Registration Statement File No.

September 9, 2021 424B5

CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be Registered Maximum Offering Price Per Unit Maximum Aggregate Offering Price Amount of Registration Fee (1) 0.550% Senior Notes due September 15, 2023 $500

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-230425 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be Registered Maximum Offering Price Per Unit Maximum Aggregate Offering Price Amount of Registration Fee (1) 0.550% Senior Notes due September 15, 2023 $500,000,000 99.964% $499,820,000 $54,530.37 0.850% Senior Notes due Septem

September 8, 2021 424B5

Subject to Completion Preliminary Prospectus Supplement dated September 8, 2021

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-230425 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not p

August 25, 2021 8-K

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commission

August 25, 2021 EX-99.1

CREDIT AGREEMENT Dated as of August 24, 2021 PERKINELMER, INC., PERKINELMER HEALTH SCIENCES, INC., PERKINELMER LIFE SCIENCES INTERNATIONAL HOLDINGS, PERKINELMER GLOBAL HOLDINGS S.À R.L, PERKINELMER HEALTH SCIENCES B.V. CERTAIN OTHER SUBSIDIARIES OF P

Exhibit 99.1 EXECUTION VERSION Published CUSIP Numbers: Deal: 71404HAL9 Revolver: 71404HAM7 CREDIT AGREEMENT Dated as of August 24, 2021 among PERKINELMER, INC., PERKINELMER HEALTH SCIENCES, INC., PERKINELMER LIFE SCIENCES INTERNATIONAL HOLDINGS, PERKINELMER GLOBAL HOLDINGS S.? R.L, PERKINELMER HEALTH SCIENCES B.V. and CERTAIN OTHER SUBSIDIARIES OF PERKINELMER, INC., as Borrowers, BANK OF AMERICA,

August 12, 2021 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commission

August 12, 2021 EX-99.1

TERM LOAN CREDIT AGREEMENT Dated as of August 11, 2021 PERKINELMER, INC., as the Borrower, BANK OF AMERICA, N.A., as the Administrative Agent, GOLDMAN SACHS BANK USA as Syndication Agent, JPMORGAN CHASE BANK, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATI

Exhibit 99.1 EXECUTION VERSION TERM LOAN CREDIT AGREEMENT Dated as of August 11, 2021 among PERKINELMER, INC., as the Borrower, BANK OF AMERICA, N.A., as the Administrative Agent, GOLDMAN SACHS BANK USA as Syndication Agent, JPMORGAN CHASE BANK, N.A. and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Co-Documentation Agents, and The Other Lenders Party Hereto GOLDMAN SACHS BANK USA, BANK OF AMERICA, N

August 10, 2021 10-Q

Number of Shares Weighted- Average Grant- Date Fair Value (In thousands) Nonvested at January 3, 2021 296 $ 85.67 Granted 102 129.27 Vested (102) 83.16 Forfeited (5) 86.90 Nonvested at July 4, 2021 291 $ 101.83

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 4, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-

July 27, 2021 EX-99.1

PerkinElmer to Acquire Antibody and Reagent Leader BioLegend Transformative deal significantly scales leading position in life science to accelerate legendary discoveries in precision medicine

Exhibit 99.1 PerkinElmer to Acquire Antibody and Reagent Leader BioLegend Transformative deal significantly scales leading position in life science to accelerate legendary discoveries in precision medicine ? Leader in antibody development with highly complementary, innovative portfolio in emerging, high-growth areas of biologics, cell and gene therapy, proteogenomics, and recombinant proteins ? Co

July 27, 2021 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commission Fi

July 27, 2021 EX-2.1

Agreement and Plan of Merger, dated as of July 25, 2021, by and among PerkinElmer, Inc., Burton Acquisition I, Inc., Burton Acquisition II, Inc., BioLegend, Inc. and Gene Lay, solely in his capacity as the Stockholder Representative, filed with the Commission on July 27, 2021 as Exhibit 2.1 to our current report on Form 8-K (File No. 001-05075) and herein incorporated by reference.

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among PERKINELMER, INC. BURTON ACQUISITION I, INC. BURTON ACQUISITION II, INC. BIOLEGEND, INC., and GENE LAY, solely in his capacity as STOCKHOLDER REPRESENTATIVE Dated as of July 25, 2021 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 Section 1.1 Certain Defined Terms 2 Section 1.2 Table of Definitions 17 ARTICLE II THE MERGER 20 Section 2.1 The Merger 20

July 26, 2021 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization

July 26, 2021 EX-99.1

PerkinElmer Announces Financial Results for the Second Quarter of 2021

Exhibit 99.1 PerkinElmer Announces Financial Results for the Second Quarter of 2021 Revenue of $1.228 billion; 51% reported growth; 41% organic growth GAAP EPS from continuing operations of $2.19; Adjusted EPS of $2.83 Initiates Third Quarter and Raises Full-Year Revenue and Earnings Guidance Announces Agreement to Acquire BioLegend ? Leading Antibody & Research Reagent Provider Earnings Call Move

June 24, 2021 EX-99.1

PerkinElmer Provides Update on Second Quarter Performance and Schedules Earnings Call for Wednesday, July 28, 2021

Exhibit 99.1 PerkinElmer Provides Update on Second Quarter Performance and Schedules Earnings Call for Wednesday, July 28, 2021 Company anticipates 2Q21 revenue and earnings to be above previously communicated guidance WALTHAM, Mass.-(BUSINESS WIRE)-June 24, 2021-PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced ahead of this morning?s Vi

June 24, 2021 8-K

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization

June 16, 2021 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-05075 A. Full t

June 1, 2021 EX-1.01

PerkinElmer, Inc. Conflict Minerals Report For the Year Ended December 31, 2020

Exhibit 1.01 PerkinElmer, Inc. Conflict Minerals Report For the Year Ended December 31, 2020 Overview PerkinElmer, Inc. (?PerkinElmer? or the ?Company?) is filing this Conflict Minerals Report (?Report?) pursuant to Rule 13p-1 and Form SD under the Securities Exchange Act of 1934 (the ?Rule?), for the reporting period January 1, 2020 through December 31, 2020. The Rule requires companies that repo

June 1, 2021 SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.) 940 Winter Street, Waltham, Massachusetts 02451 (Address of

May 11, 2021 EX-10.2

Form of Restricted Stock Unit Agreement (Performance-based vesting) with double-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, filed with the Commission on May 11, 2021 as Exhibit 10.2 to our quarterly report on Form 10-Q (File No. 001-05075) and herein incorporated by reference.

Performance RSU (Double Trigger) EXHIBIT 10.2 01/20/21 PERKINELMER, INC. Restricted Stock Unit Agreement 2019 Incentive Plan This Restricted Stock Unit Agreement is made as of the Grant Date set forth below between PerkinElmer, Inc., a Massachusetts corporation (the ?Company?), and the Participant named below. NOTICE OF GRANT Name of Participant (the ?Participant?): [PARTICIPANT NAME] Grant Date:

May 11, 2021 10-Q

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 4, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001

May 11, 2021 EX-10.1

Form of Restricted Stock Unit Agreement (Performance-based vesting) with single-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, filed with the Commission on May 11, 2021 as Exhibit 10.1 to our quarterly report on Form 10-Q (File No. 001-05075) and herein incorporated by reference.

Performance RSU (Single Trigger) 01/20/21 EXHIBIT 10.1 PERKINELMER, INC. Restricted Stock Unit Agreement 2019 Incentive Plan This Restricted Stock Unit Agreement is made as of the Grant Date set forth below between PerkinElmer, Inc., a Massachusetts corporation (the ?Company?), and the Participant named below. NOTICE OF GRANT Name of Participant (the ?Participant?): [PARTICIPANT NAME] Grant Date:

May 11, 2021 EX-10.3

Form of Restricted Stock Agreement with single-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, filed with the Commission on May 11, 2021 as Exhibit 10.3 to our quarterly report on Form 10-Q (File No. 001-05075) and herein incorporated by reference.

Restricted Stock (Single Trigger) EXHIBIT 10.3 01/20/21 PERKINELMER, INC. Restricted Stock Agreement 2019 Stock Incentive Plan This Restricted Stock Agreement is made as of the Grant Date set forth below between PerkinElmer, Inc., a Massachusetts corporation (the ?Company?), and the Participant named below. NOTICE OF GRANT Name of Participant (the ?Participant?): Grant Date: Number of shares of th

May 11, 2021 EX-10.5

PerkinElmer, Inc. Amended and Restated Global Incentive Compensation Plan (Executive Officers) effective January 4, 2021, attached hereto as Exhibit 10.5.

EXHIBIT 10.5 PerkinElmer, Inc. Amended and Restated Global Incentive Compensation Plan (Executive Officers) effective January 4, 2021 1. PURPOSE 1.1 The Global Incentive Compensation Plan(?Plan?) provides senior and other key leaders with an opportunity to earn annual cash bonus awards based on the achievement of financial and non-financial objectives. This document governs the policy and administ

May 11, 2021 EX-10.4

Form of Restricted Stock Agreement with double-trigger vesting acceleration upon a change of control for grants to executive officers under the 2019 Incentive Plan, filed with the Commission on May 11, 2021 as Exhibit 10.4 to our quarterly report on Form 10-Q (File No. 001-05075) and herein incorporated by reference.

Restricted Stock (Double Trigger) EXHIBIT 10.4 01/20/21 PERKINELMER, INC. Restricted Stock Agreement 2019 Stock Incentive Plan This Restricted Stock Agreement is made as of the Grant Date set forth below between PerkinElmer, Inc., a Massachusetts corporation (the ?Company?), and the Participant named below. NOTICE OF GRANT Name of Participant (the ?Participant?): Grant Date: Number of shares of th

May 4, 2021 EX-99.1

PerkinElmer Announces Financial Results for the First Quarter of 2021

Exhibit 99.1 PerkinElmer Announces Financial Results for the First Quarter of 2021 Revenue of $1.308 billion; 100% reported growth; 92% organic growth GAAP EPS from continuing operations of $3.37; Adjusted EPS of $3.72 Initiates Second Quarter and Raises Full-Year Revenue and Earnings Guidance WALTHAM, Mass.-(BUSINESS WIRE)-May 4, 2021-PerkinElmer, Inc. (NYSE: PKI), a global leader committed to in

May 4, 2021 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization)

April 30, 2021 8-K

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commission F

April 13, 2021 EX-99.1

PerkinElmer Provides First Quarter Update and Schedules Earnings Call for Tuesday, May 4, 2021

Exhibit 99.1 PerkinElmer Provides First Quarter Update and Schedules Earnings Call for Tuesday, May 4, 2021 Company also announces appointment of Steve Willoughby as vice president, investor relations WALTHAM, Mass.-(BUSINESS WIRE)-April 13, 2021-PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic re

April 13, 2021 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizatio

April 9, 2021 EX-99.25

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on April 20, 2021, pursuant to the provisions of Rule 12d2-2 (a).

March 10, 2021 DEFA14A

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of

March 10, 2021 DEF 14A

definitive proxy statement

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid

March 8, 2021 EX-4.2

Sixth Supplemental Indenture, dated as of March 8, 2021, by and between the Company and U.S. Bank National Association, as trustee (including the form of note contained therein)

Exhibit 4.2 PERKINELMER, INC. $400,000,000 2.550% Senior Notes due 2031 $400,000,000 3.625% Senior Notes due 2051 SIXTH SUPPLEMENTAL INDENTURE Dated as of March 8, 2021 to Indenture Dated as of October 25, 2011 U.S. Bank National Association, as Trustee This SIXTH SUPPLEMENTAL INDENTURE (this ?Supplemental Indenture?) dated as of March 8, 2021, to the Indenture (the ?Existing Indenture?) dated as

March 8, 2021 EX-1.1

Underwriting Agreement, dated March 4, 2021, by and among the Company and J.P. Morgan Securities LLC and BofA Securities, Inc., as representatives of the several underwriters named in the Underwriting Agreement.

Exhibit 1.1 PerkinElmer, Inc. $800,000,000 2.550% Senior Notes due 2031 3.625% Senior Notes due 2051 UNDERWRITING AGREEMENT March 4, 2021 TABLE OF CONTENTS PAGE Section 1. Representations and Warranties of the Company 5 Section 2. Purchase, Sale and Delivery of the Notes 16 Section 3. Covenants of the Company 17 Section 4. Payment of Expenses 21 Section 5. Conditions of the Obligations of the Unde

March 8, 2021 424B5

CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be Registered Maximum Offering Price Per Unit Maximum Aggregate Offering Price Amount of Registration Fee (1) 2.550% Senior Notes due March 15, 2031 $400,000

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-230425 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be Registered Maximum Offering Price Per Unit Maximum Aggregate Offering Price Amount of Registration Fee (1) 2.550% Senior Notes due March 15, 2031 $400,000,000 99.965% $399,860,000 $43,624.73 3.625% Senior Notes due March 15,

March 8, 2021 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commission Fi

March 4, 2021 FWP

Final Term Sheet

Final Term Sheet Free Writing Prospectus Filed pursuant to Rule 433 To Prospectus dated March 21, 2019 Preliminary Prospectus Supplement dated March 4, 2021 Registration Statement File No.

March 4, 2021 424B5

Subject to Completion Preliminary Prospectus Supplement dated March 4, 2021

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-230425 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitt

March 2, 2021 EX-21

Subsidiaries of PerkinElmer, Inc., attached hereto as Exhibit 21.

EXHIBIT 21 Subsidiaries of the Registrant As of March 2, 2021, the following is a list of the parent (Registrant) and its active subsidiaries, together with their subsidiaries.

March 2, 2021 EX-10.16

PerkinElmer, Inc. Savings Plan Amended and Restated effective January 1, 2021, filed with the Commission on March 2, 2021 as Exhibit 10.16 to our annual report on Form 10-K (File No. 001-05075) and herein incorporated by reference.

EXHIBIT 10.16 PERKINELMER, INC. SAVINGS PLAN (Amended and Restated Effective January 1, 2021) ActiveUS 185195340v.3 TABLE OF CONTENTS APPENDICES Article I - DEFINITIONS 2 1.1 ?Account? 2 1.2 ?Actual Deferral Percentage? 2 1.3 ?Adjustment Factor? 2 1.4 ?Administrator? 2 1.5 ?After-Tax Contribution Account? 2 1.6 ?After-Tax Contributions? 2 1.7 ?Annual Addition? 2 1.8 ?Authorized Leave of Absence? 2

March 2, 2021 10-K

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 3, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-5075 PerkinElmer, Inc.

February 16, 2021 SC 13G/A

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7 )* PerkinElmer, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 714046109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

February 12, 2021 EX-99.1

EXHIBIT 99.1

EXHIBIT 99.1 The identity and the Item 3 classification of the relevant subsidiary are: Select Equity Group, L.P., which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

February 12, 2021 SC 13G/A

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* PerkinElmer, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) December 31, 2020 (Dat

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* PerkinElmer, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 714046109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed

February 10, 2021 SC 13G/A

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: PerkinElmer Inc. Title of Class of Securities: Common Stock CUSIP Number: 714046109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ R

February 2, 2021 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition - PERKINELMER, INC. 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizat

February 2, 2021 EX-99.1

PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2020

Exhibit 99.1 PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2020 4Q Revenue of $1.355 billion; 68% reported growth; 65% organic growth 4Q GAAP EPS from continuing operations of $3.38; Adjusted EPS of $3.96 Initiates First Quarter and Full Year 2021 Guidance WALTHAM, Mass.-(BUSINESS WIRE)-February 2, 2021-PerkinElmer, Inc. (NYSE: PKI), a global leader committed to i

January 11, 2021 EX-99.1

SAFE HARBOR This presentation contains forward-looking statements which are statements relating to future events. These statements include those relating to estimates and projections of future earnings per share, cash flow and revenue growth and othe

EX-99.1 Exhibit 99.1 J.P. MORGAN Healthcare Conference Prahlad Singh Chief Executive Officer January 11, 2021 1Exhibit 99.1 J.P. MORGAN Healthcare Conference Prahlad Singh Chief Executive Officer January 11, 2021 1 SAFE HARBOR This presentation contains forward-looking statements which are statements relating to future events. These statements include those relating to estimates and projections of

January 11, 2021 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition - PERKINELMER, INC. 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizat

January 11, 2021 EX-99.1

PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 2, 2021

Exhibit 99.1 PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 2, 2021 WALTHAM, Mass.-(BUSINESS WIRE)-January 11, 2021-PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of approximately 66% and 63%, respectively, GAAP earnings per share from conti

January 11, 2021 DEFA14A

- DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or O

January 11, 2021 EX-99.2

JP Morgan 39th Annual Healthcare Virtual Conference

EX-99.2 Exhibit 99.2 FINAL TRANSCRIPT JP Morgan 39th Annual Healthcare Virtual Conference Company Participants James M. Mock, Senior VP & CFO Prahlad R. Singh, CEO, President &Director Masoud Toloue, VP/GM, Diagnostics Other Participants Tycho W. Peterson, Senior Analyst, JP Morgan Presentation Tycho W. Peterson Good morning, everybody. Welcome to day one of the JPMorgan Healthcare Conference. I’m

January 11, 2021 8-K

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizat

January 7, 2021 DEFA14A

- DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Or

January 7, 2021 8-K

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2021 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizati

January 7, 2021 EX-99.1

PerkinElmer to Acquire Oxford Immunotec Global PLC

EX-99.1 Exhibit 99.1 PerkinElmer to Acquire Oxford Immunotec Global PLC • PerkinElmer to acquire Oxford Immunotec for USD 22.00 per share in cash • Transaction expected to be completed in the first half of 2021 WALTHAM, Mass. and LONDON, January 7, 2021 – PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) (“Oxford Immunotec” or the “Company”) are pleased t

November 10, 2020 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 4, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0

October 28, 2020 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition - PERKINELMER, INC. 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizat

October 28, 2020 EX-99.1

PerkinElmer Announces Financial Results for the Third Quarter of 2020

Exhibit 99.1 PerkinElmer Announces Financial Results for the Third Quarter of 2020 Revenue of $964.0 million; 36% reported growth; 34% organic growth GAAP EPS from continuing operations of $1.57; Adjusted EPS of $2.09 WALTHAM, Mass.-(BUSINESS WIRE)-October 28, 2020-PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the

October 13, 2020 EX-99.1

Contacts

Exhibit 99.1 PerkinElmer Updates Third Quarter Outlook; To Hold Earnings Call on Wednesday, October 28, 2020 WALTHAM, Mass.-(BUSINESS WIRE)-October 12, 2020-PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of approximately 35% and 33%, respectively, for the third quarter ended Octob

October 13, 2020 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition - PERKINELMER, INC. 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2020 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizat

August 11, 2020 10-Q

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 5, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-

July 28, 2020 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2020 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization

July 28, 2020 EX-99.1

PerkinElmer Announces Financial Results for the Second Quarter of 2020

Exhibit 99.1 PerkinElmer Announces Financial Results for the Second Quarter of 2020 Revenue of $811.7 million; 12% reported growth; 13% organic growth GAAP EPS from continuing operations of $1.23; Adjusted EPS of $1.57 WALTHAM, Mass.-(BUSINESS WIRE)-July 28, 2020-PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the s

July 13, 2020 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2020 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization

July 13, 2020 EX-99.1

PerkinElmer Updates Second Quarter Outlook; To Hold Earnings Call on Tuesday, July 28, 2020

Exhibit 99.1 PerkinElmer Updates Second Quarter Outlook; To Hold Earnings Call on Tuesday, July 28, 2020 WALTHAM, Mass.-(BUSINESS WIRE)-July 13, 2020-PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates growth in both reported revenue and organic revenue1 of approximately 12% for the second quarter ended July 5, 2020. The

June 18, 2020 11-K

- 11-K

11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-05075 A. Full title of the p

June 1, 2020 SD

- SD

SD 1 d928280dsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of (Commission (IRS Employer Incorporation or Organization) File Number) Identification No.) 940 Winter Street, Waltham, Massachus

June 1, 2020 EX-1.01

PerkinElmer, Inc. Conflict Minerals Report For the Year Ended December 31, 2019

EX-1.01 Exhibit 1.01 PerkinElmer, Inc. Conflict Minerals Report For the Year Ended December 31, 2019 Overview PerkinElmer, Inc. (“PerkinElmer” or the “Company”) is filing this Conflict Minerals Report (“Report”) pursuant to Rule 13p-1 and Form SD under the Securities Exchange Act of 1934 (the “Rule”), for the reporting period January 1, 2019 through December 31, 2019. The Rule requires companies t

May 12, 2020 EX-10.1

Second Amendment to Credit Agreement, dated as of February 27, 2020, among PerkinElmer, Inc., PerkinElmer Health Sciences, Inc., PerkinElmer Life Sciences International Holdings, PerkinElmer Global Holdings S.à r.l. and PerkinElmer Health Sciences B.V., as Borrowers, Bank of America, N.A. as Administrative Agent, Swing Line Lender and an L/C Issuer, the Lenders party thereto and the other L/C Issuers party thereto, attached hereto as Exhibit 10.1.

EXHIBIT 10.1 EXECUTION VERSION SECOND AMENDMENT TO CREDIT AGREEMENT THIS SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is entered into as of February 27, 2020 among PERKINELMER, INC., a Massachusetts corporation (the “Company”), PERKINELMER HEALTH SCIENCES, INC., a Delaware corporation (“Health Sciences”), PERKINELMER LIFE SCIENCES INTERNATIONAL HOLDINGS, a company incorporated and regis

May 12, 2020 10-Q

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 5, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001

May 5, 2020 EX-99.1

PerkinElmer Announces Financial Results for the First Quarter of 2020

Exhibit 99.1 PerkinElmer Announces Financial Results for the First Quarter of 2020 Revenue of $652.4 million; 1% reported growth; (1)% organic growth GAAP EPS from continuing operations of $0.30; Adjusted EPS of $0.67 Withdrawing previously disseminated FY20 guidance due to COVID-related uncertainties WALTHAM, Mass.-(BUSINESS WIRE)-May 5, 2020-PerkinElmer, Inc. (NYSE: PKI), a global leader committ

May 5, 2020 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization)

May 1, 2020 8-K

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2020 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commission F

April 14, 2020 DEFA14A

PKI / PerkinElmer, Inc. DEFA14A - - DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

April 1, 2020 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2020 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation) (Commission F

April 1, 2020 EX-99.1

PERKINELMER, INC. Restricted Stock Unit Agreement 2019 Stock Incentive Plan

EX-99.1 Exhibit 99.1 Time-Vested RSU (Single Trigger) PERKINELMER, INC. Restricted Stock Unit Agreement 2019 Stock Incentive Plan This Restricted Stock Unit Agreement is made as of the Grant Date set forth below between PerkinElmer, Inc., a Massachusetts corporation (the “Company”), and the Participant named below. NOTICE OF GRANT Name of Participant (the “Participant”): Grant Date: Number of Rest

April 1, 2020 EX-99.2

PERKINELMER, INC. Restricted Stock Unit Agreement 2019 Stock Incentive Plan

EX-99.2 Exhibit 99.2 Time-Vested RSU (Double Trigger) PERKINELMER, INC. Restricted Stock Unit Agreement 2019 Stock Incentive Plan This Restricted Stock Unit Agreement is made as of the Grant Date set forth below between PerkinElmer, Inc., a Massachusetts corporation (the “Company”), and the Participant named below. NOTICE OF GRANT Name of Participant (the “Participant”): Grant Date: Number of Rest

March 25, 2020 8-K

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2020 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organizatio

March 11, 2020 DEF 14A

PKI / PerkinElmer, Inc. DEF 14A - - DEF 14A

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

March 11, 2020 DEFA14A

PKI / PerkinElmer, Inc. DEFA14A - - DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo

March 9, 2020 EX-99.1

PerkinElmer First Quarter 2020 Financial Performance Update

EX-99.1 2 d900570dex991.htm EX-99.1 Exhibit 99.1 PerkinElmer First Quarter 2020 Financial Performance Update WALTHAM, Mass. – March 9, 2020 – PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it expects first quarter 2020 revenue and earnings per share, both on a GAAP and non-GAAP basis, to be below the Company’s previously communica

March 9, 2020 8-K

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2020 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization

March 2, 2020 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2020 PerkinElmer, Inc. (Exact Name of Registrant as Specified in its Charter) Massachusetts 001-05075 04-2052042 (State or Other Jurisdiction of Incorporation or Organization

February 25, 2020 10-K

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 29, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-5075 PerkinElmer, Inc.

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista